Side-by-side · Research reference
EpitalonvsPE 22-28
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticAUTO-DRAFTED8/37 cited
BAnimal-StrongHUMAN-REVIEWED16/47 cited
Epitalon
Pineal bioregulator · Telomerase activator
SQ or IM · Abdomen · Daily for 10–20 days
PE 22-28
TREK-1 Antagonist · Pre-Clinical
IP · SQ · Once Daily (animal models)Djillani 2017Pietri 2019
01Mechanism of Action
Parameter
Epitalon
PE 22-28
Primary target
Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003
TREK-1 two-pore-domain potassium channelDjillani 2017Ma 2020
Pathway
Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003
TREK-1 channel blockade → Neuronal membrane depolarisation → Enhanced hippocampal excitability → Increased neuroplasticity
Downstream effect
Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003
Antidepressant-like activity in forced swim test and tail suspension test; reduced A1-like reactive astrocyte activation; neuroprotection via NF-κB pathway modulationDjillani 2017Cong 2023Wu 2021
Feedback intact?
—
N/A — direct ion channel blockade; not receptor-mediated endocrine axis
Origin
Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003
Synthetic truncation of spadin (PE 12-28), itself derived from the sortilin propeptide C-terminus. Residues 22-28: Val-Val-Arg-Gly-Trp-Leu-Arg.Djillani 2017Mazella 2018
Antibody development
—
Not reported in animal studies
02Dosage Protocols
Parameter
Epitalon
PE 22-28
Standard dose
5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003
Anecdotal community protocol. Russian clinical literature uses similar cycling.
—
Frequency
Once daily during a cycle
Once daily
Sustained antidepressant effect over 7+ days.
Lower / starter dose
2.5 mg / day
—
Evidence basis
In-vitro telomerase + Russian clinical trialsKhavinson 2003
Multiple rodent RCTs; behavioral + electrophysiology endpointsDjillani 2017Qi 2018Wu 2021
Duration
10–20 day cycles, 1–2× per year
—
Reconstitution
Bacteriostatic water
—
Timing
Pre-sleep preferred (pineal alignment)
—
Half-life
Hours (estimated)
—
Animal dose (antidepressant)
—
0.3–3 µg/kg IP
Effective in forced swim test, tail suspension test, CUMS models.
Animal dose (neuroprotection)
—
0.03 µg/kg IPPietri 2019
Low-dose TREK-1 activation post-stroke for 7 days, then high-dose blockade.
Onset (animal)
—
Within hours (acute); full effect 4–7 days
Comparison to fluoxetine
—
PE 22-28 outperforms fluoxetine in CUMS-sensitive rats by day 7
Chronic administration shows superior long-term efficacy.
Human equivalent (extrapolated)
—
Not established — no clinical trials
Allometric scaling from rodent data unavailable.
04Side Effects & Safety
Parameter
Epitalon
PE 22-28
Injection site reaction
Mild irritation
—
Sleep architecture
Improved subjective sleep quality (anecdotal)
—
Cancer risk
Theoretical via telomerase activation in pre-malignant cells
—
Long-term safety
Limited Western RCT data
Unknown — longest animal study 28 days
Pregnancy / OB
Avoid
—
Antibody formation
Not reported
—
Toxicity (animal)
—
No adverse effects reported at therapeutic doses
Cardiovascular (theoretical)
—
TREK-1 expressed in cardiac tissue; arrhythmia risk unclear
Weight change
—
Not reported in animal studies
Neurological
—
No seizures or behavioral abnormalities noted
Absolute Contraindications
Epitalon
- ·Pregnancy / breastfeeding
- ·Active malignancy or pre-malignant state
PE 22-28
- ·Human use — no clinical safety data available
Relative Contraindications
Epitalon
- ·Family history of cancer
PE 22-28
- ·Cardiac arrhythmia or channelopathy (theoretical TREK-1 cardiac role)
05Administration Protocol
Parameter
Epitalon
PE 22-28
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.
Dissolved in sterile saline or vehicle. Intraperitoneal injection, 0.3–3 µg/kg body weight. Once daily administration in rodent behavioral studies.
2. Injection site
SQ — abdomen preferred. Rotate sites.
Shorter peptide length (7 AA) confers improved plasma stability vs 17-AA spadin. Exact storage conditions not detailed in published protocols.Djillani 2017
3. Timing
Pre-sleep preferred to align with pineal axis.
Enhanced CNS bioavailability vs full spadin, likely due to smaller size. Mechanism (passive diffusion vs active transport) not fully characterized.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Not established — peptide synthesis methods for research use only. No pharmaceutical-grade formulation available.
5. Needle
29–31G, 4–8 mm insulin syringe.
—